CD23+ mantle cell lymphoma: A clinical pathologic entity associated with superior outcome compared with CD23- disease

Katalin Kelemen, LoAnn C. Peterson, Irene Helenowski, Charles L. Goolsby, Borko Jovanovic, Sarah Miyata, Olivia Aranha, Steven T. Rosen, Jane N. Winter, Beverly P. Nelson, Leo I. Gordon, Andrew M. Evens

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) commonly lacks expression of CD23. However, a significant minority of MCLs express CD23, as assessed by flow cytometric immunophenotyping (FCIP). The aims of our study were to investigate the expression of CD23 by FCIP in patients with MCL and to correlate CD23 expression with pathologic and clinical parameters, including outcome. We studied 53 patients with untreated MCL who had CD23 expression determined by FCIP. At diagnosis, 14 MCLs (26%) were CD23+ at all tissue sites, whereas 33 (62%) were CD23-, and 6 (11%) had discordant CD23 expression among different tissue sites. Patients with CD23- MCL had extranodal disease more commonly compared with patients with CD23+ MCL. Moreover, with 57-month median follow-up, the 4-year event-free and overall survival rates for CD23+ MCL were 45% and 75%, respectively, compared with 19% and 51% for CD23- MCL. In multivariate Cox regression analysis, CD23 status and leukemicphase MCL were the most important factors predicting outcome.

Original languageEnglish (US)
Pages (from-to)166-177
Number of pages12
JournalAmerican Journal of Clinical Pathology
Volume130
Issue number2
DOIs
StatePublished - Aug 1 2008
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Immunophenotyping
Disease-Free Survival
Survival Rate
Regression Analysis

Keywords

  • CD23
  • Disease outcome
  • Flow cytometric immunophenotyping
  • Mantle cell lymphoma
  • Prognosis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

CD23+ mantle cell lymphoma : A clinical pathologic entity associated with superior outcome compared with CD23- disease. / Kelemen, Katalin; Peterson, LoAnn C.; Helenowski, Irene; Goolsby, Charles L.; Jovanovic, Borko; Miyata, Sarah; Aranha, Olivia; Rosen, Steven T.; Winter, Jane N.; Nelson, Beverly P.; Gordon, Leo I.; Evens, Andrew M.

In: American Journal of Clinical Pathology, Vol. 130, No. 2, 01.08.2008, p. 166-177.

Research output: Contribution to journalArticle

Kelemen, K, Peterson, LC, Helenowski, I, Goolsby, CL, Jovanovic, B, Miyata, S, Aranha, O, Rosen, ST, Winter, JN, Nelson, BP, Gordon, LI & Evens, AM 2008, 'CD23+ mantle cell lymphoma: A clinical pathologic entity associated with superior outcome compared with CD23- disease', American Journal of Clinical Pathology, vol. 130, no. 2, pp. 166-177. https://doi.org/10.1309/R94MAFJY5EA4A8C3
Kelemen, Katalin ; Peterson, LoAnn C. ; Helenowski, Irene ; Goolsby, Charles L. ; Jovanovic, Borko ; Miyata, Sarah ; Aranha, Olivia ; Rosen, Steven T. ; Winter, Jane N. ; Nelson, Beverly P. ; Gordon, Leo I. ; Evens, Andrew M. / CD23+ mantle cell lymphoma : A clinical pathologic entity associated with superior outcome compared with CD23- disease. In: American Journal of Clinical Pathology. 2008 ; Vol. 130, No. 2. pp. 166-177.
@article{f57f2cc7a0ee457e8cbb5305fea6c9b6,
title = "CD23+ mantle cell lymphoma: A clinical pathologic entity associated with superior outcome compared with CD23- disease",
abstract = "Mantle cell lymphoma (MCL) commonly lacks expression of CD23. However, a significant minority of MCLs express CD23, as assessed by flow cytometric immunophenotyping (FCIP). The aims of our study were to investigate the expression of CD23 by FCIP in patients with MCL and to correlate CD23 expression with pathologic and clinical parameters, including outcome. We studied 53 patients with untreated MCL who had CD23 expression determined by FCIP. At diagnosis, 14 MCLs (26{\%}) were CD23+ at all tissue sites, whereas 33 (62{\%}) were CD23-, and 6 (11{\%}) had discordant CD23 expression among different tissue sites. Patients with CD23- MCL had extranodal disease more commonly compared with patients with CD23+ MCL. Moreover, with 57-month median follow-up, the 4-year event-free and overall survival rates for CD23+ MCL were 45{\%} and 75{\%}, respectively, compared with 19{\%} and 51{\%} for CD23- MCL. In multivariate Cox regression analysis, CD23 status and leukemicphase MCL were the most important factors predicting outcome.",
keywords = "CD23, Disease outcome, Flow cytometric immunophenotyping, Mantle cell lymphoma, Prognosis",
author = "Katalin Kelemen and Peterson, {LoAnn C.} and Irene Helenowski and Goolsby, {Charles L.} and Borko Jovanovic and Sarah Miyata and Olivia Aranha and Rosen, {Steven T.} and Winter, {Jane N.} and Nelson, {Beverly P.} and Gordon, {Leo I.} and Evens, {Andrew M.}",
year = "2008",
month = "8",
day = "1",
doi = "10.1309/R94MAFJY5EA4A8C3",
language = "English (US)",
volume = "130",
pages = "166--177",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - CD23+ mantle cell lymphoma

T2 - A clinical pathologic entity associated with superior outcome compared with CD23- disease

AU - Kelemen, Katalin

AU - Peterson, LoAnn C.

AU - Helenowski, Irene

AU - Goolsby, Charles L.

AU - Jovanovic, Borko

AU - Miyata, Sarah

AU - Aranha, Olivia

AU - Rosen, Steven T.

AU - Winter, Jane N.

AU - Nelson, Beverly P.

AU - Gordon, Leo I.

AU - Evens, Andrew M.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Mantle cell lymphoma (MCL) commonly lacks expression of CD23. However, a significant minority of MCLs express CD23, as assessed by flow cytometric immunophenotyping (FCIP). The aims of our study were to investigate the expression of CD23 by FCIP in patients with MCL and to correlate CD23 expression with pathologic and clinical parameters, including outcome. We studied 53 patients with untreated MCL who had CD23 expression determined by FCIP. At diagnosis, 14 MCLs (26%) were CD23+ at all tissue sites, whereas 33 (62%) were CD23-, and 6 (11%) had discordant CD23 expression among different tissue sites. Patients with CD23- MCL had extranodal disease more commonly compared with patients with CD23+ MCL. Moreover, with 57-month median follow-up, the 4-year event-free and overall survival rates for CD23+ MCL were 45% and 75%, respectively, compared with 19% and 51% for CD23- MCL. In multivariate Cox regression analysis, CD23 status and leukemicphase MCL were the most important factors predicting outcome.

AB - Mantle cell lymphoma (MCL) commonly lacks expression of CD23. However, a significant minority of MCLs express CD23, as assessed by flow cytometric immunophenotyping (FCIP). The aims of our study were to investigate the expression of CD23 by FCIP in patients with MCL and to correlate CD23 expression with pathologic and clinical parameters, including outcome. We studied 53 patients with untreated MCL who had CD23 expression determined by FCIP. At diagnosis, 14 MCLs (26%) were CD23+ at all tissue sites, whereas 33 (62%) were CD23-, and 6 (11%) had discordant CD23 expression among different tissue sites. Patients with CD23- MCL had extranodal disease more commonly compared with patients with CD23+ MCL. Moreover, with 57-month median follow-up, the 4-year event-free and overall survival rates for CD23+ MCL were 45% and 75%, respectively, compared with 19% and 51% for CD23- MCL. In multivariate Cox regression analysis, CD23 status and leukemicphase MCL were the most important factors predicting outcome.

KW - CD23

KW - Disease outcome

KW - Flow cytometric immunophenotyping

KW - Mantle cell lymphoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=48649106006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48649106006&partnerID=8YFLogxK

U2 - 10.1309/R94MAFJY5EA4A8C3

DO - 10.1309/R94MAFJY5EA4A8C3

M3 - Article

C2 - 18628084

AN - SCOPUS:48649106006

VL - 130

SP - 166

EP - 177

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -